dalpiciclib
E1555608
UNEXPLORED
Dalpiciclib is an investigational small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) being developed primarily for the treatment of hormone receptor–positive breast cancer.
All labels observed (1)
| Label | Occurrences |
|---|---|
| dalpiciclib canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T22796790 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: dalpiciclib Context triple: [CDK6, isDrugTargetOf, dalpiciclib]
-
A.
trilaciclib
Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor used to protect bone marrow from chemotherapy-induced damage in patients with certain cancers.
-
B.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
C.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: dalpiciclib Target entity description: Dalpiciclib is an investigational small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) being developed primarily for the treatment of hormone receptor–positive breast cancer.
-
A.
trilaciclib
Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor used to protect bone marrow from chemotherapy-induced damage in patients with certain cancers.
-
B.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
C.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.